A5001112070- Hemophilia Treatment and Research
- Toxic Organic Pollutants Impact
- Carcinogens and Genotoxicity Assessment
- Monoclonal and Polyclonal Antibodies Research
- Blood Coagulation and Thrombosis Mechanisms
- Biosimilars and Bioanalytical Methods
- Protein purification and stability
- Pesticide Exposure and Toxicity
- Pharmacology and Obesity Treatment
- Cancer Research and Treatments
- Plant-based Medicinal Research
- Immunotoxicology and immune responses
- Blood transfusion and management
- Platelet Disorders and Treatments
- CAR-T cell therapy research
- Nanoparticle-Based Drug Delivery
- Forensic Toxicology and Drug Analysis
- Transgenic Plants and Applications
- Alcohol Consumption and Health Effects
- Environmental Toxicology and Ecotoxicology
- 3D Printing in Biomedical Research
- Poisoning and overdose treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood groups and transfusion
- Toxin Mechanisms and Immunotoxins
Bayer (United States)
1998-2019
Bayer (Germany)
1989-1993
A set of four learning and memory tests (Morris Maze I for reference memory, Morris II working one-way active avoidance, passive avoidance) were employed to address the questions whether parathion impaired cognitive functions after low, long-term exposure could cause persistent changes in cognition. Motor activity general behavior investigated a functional observational battery. Parathion was administered rat food low doses which caused no clinical symptoms or borderline brain...
BAY 94-9027 (Jivi) is a site-specifically PEGylated human B-domain-deleted (BDD) recombinant factor VIII (FVIII), with 60 kDa branched PEG molecule attached. The nonclinical safety of was evaluated in toxicology program that included 2 weeks intravenous (IV) toxicity studies rats and rabbits, juvenile study as well 26-week chronic rats. Doses 75, 750, or 2250 IU/kg given every other day for did not elicit any findings related to 94-9027. Specifically, no thrombus formation histological...